共 50 条
- [21] Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell TherapyBLOOD, 2019, 134Jacobson, Caron A.Herrera, Alex F.Budde, Lihua E.DeAngelo, Daniel J.Heery, ChristopherStein, AnthonyJain, Michael D.Shah, Bijal
- [22] Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapyJOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)Li, WenjieDing, LixiaShi, WenhuaWan, XinyuYang, XiaominYang, JingWang, TianyiSong, LiliWang, XiangMa, YaniLuo, ChengjuanTang, JingyanGu, LongjunChen, JingLu, JunTang, YanjingLi, Benshang
- [23] Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T TherapyBLOOD, 2021, 138Jain, Michael D.Ziccheddu, BachisioCoughlin, Caroline A.Faramand, RawanGriswold, Anthony J.Reid, Kayla M.Landgren, OlaLocke, Frederick L.Maura, FrancescoDavila, Marco L.Schatz, Jonathan H.
- [24] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphomaHEMASPHERE, 2024, 8 (08):Gong, Inna Y.Tran, DaisySaibil, SamuelLaister, Rob C.Kuruvilla, John
- [25] CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case ReportFRONTIERS IN IMMUNOLOGY, 2022, 13Sun, ZhuanyiXie, CaiqinLiu, HuiYuan, Xianggui
- [26] Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapyEXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 653 - 664Chou, Cassie K.Turtle, Cameron J.
- [27] GENOMIC DRIVERS OF LARGE B-CELL LYMPHOMA RESISTANCE TO CD19 CAR-T THERAPYJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A703 - A703Jain, MichaelZiccheddu, BachisioCoughlin, CarolineFaramand, RawanGriswold, AnthonyReid, KaylaLandgren, OlaLocke, FrederickMaura, FrancescoDavila, MarcoSchatz, Jonathan
- [28] Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansionSCIENCE ADVANCES, 2023, 9 (38)Rejeski, KaiPerez, ArielIacoboni, GloriaBlumenberg, ViktoriaBuecklein, Veit L.Voelkl, SimonPenack, OlafAlbanyan, OmarStock, SophiaMueller, FabianKarschnia, PhilippPetrera, AgneseReid, KaylaFaramand, RawanDavila, Marco L.Modi, KarnavDean, Erin A.Bachmeier, Christinavon Bergwelt-Baildon, MichaelLocke, Frederick L.Bethge, WolfgangBullinger, LarsMackensen, AndreasBarba, PereJain, Michael D.Subklewe, Marion
- [29] Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical TrialBLOOD, 2022, 140 : 10335 - 10336Feng, JingjingHu, YongxianZhang, MingmingCao, HengKe, YiniXu, HuijunCui, JiazhenZhang, YanleiChang, Alex HongshengLin, JinWei, GuoqingHuang, He